How does 99% Racecadotril powder target enkephalinase to achieve rapid relief of acute diarrhea?
Acute infectious diarrhea and functional diarrhea have long plagued adults and children worldwide. Frequent diarrhea can easily lead to dehydration, electrolyte imbalance, and gut microbiota dysbiosis. Traditional antidiarrheal drugs have limitations in their effects and significant side effects. 99% Racecadotril powder is a novel selective enkephalinase inhibitor raw material with a purity of ≥99.0%. It is a core antidiarrheal ingredient that combines intestinal targeting, rapid onset of action, and excellent safety. By inhibiting intestinal enkephalinase and increasing endogenous enkephalin levels, it reduces excessive intestinal secretion, thus offering the advantages of stopping diarrhea, protecting the intestines, and having low central nervous system side effects. It is suitable for the treatment of diarrhea in adults and infants.
⚛️Molecular Structure｜Chiral Ester Small Molecule Backbone
99% Racecadotril powder, chemically named (±)-N-[(R,S)-3-acetylthio-2-benzylpropionyl]glycine benzyl ester, has the molecular formula C₂₁H₂₃NO₄S, a molecular weight of 385.48, and is a white crystalline powder. It has a purity ≥99.0%, with single impurities ≤0.10% and moisture ≤0.3%, meeting USP, EP, ICH-Q3 series, and cGMP standards for pharmaceutical raw materials. The molecule consists of a benzyl hydrophobic side chain, an acetylthio active group, a chiral propionyl backbone, and a polar end of glycine benzyl ester. It is a racemic chiral small molecule, unlike traditional antidiarrheal drugs, it specifically binds to intestinal endorphins, does not cross the blood-brain barrier, and has no central nervous system adverse reactions.
The acetylthio group is the core functional group that exerts the molecule's pharmacological activity. It can rapidly deacetylate in the intestine to generate the active metabolite thifencadotril, precisely anchoring to the active site of enkephalinase and blocking the enzyme's degradation of enkephalin. The 99.0% high-purity raw material strictly controls the oxidation and hydrolysis impurities of the thio group to ≤0.05%, ensuring the integrity and stability of the active group. In vitro enzyme activity tests show that the inhibitory activity against intestinal enkephalinase can reach over 92%, with a faster onset of action than similar inhibitors. Industrial synthesis employs a racemic directed synthesis process, ensuring batch-to-batch uniformity of configuration and eliminating the problem of enrichment of single chiral isomers.
The two benzyl hydrophobic groups enhance the molecule's lipophilicity, facilitating rapid penetration of intestinal epithelial cells and accumulation in intestinal mucosal tissue, achieving targeted distribution in the intestine and reducing systemic blood circulation exposure. This structure prevents the molecule from entering the central nervous system, completely avoiding the common risks of constipation, drowsiness, and addiction associated with opioid antidiarrheal drugs, making it a key structural design for intestinal-specific antidiarrheal raw materials. Accelerated stability testing showed that after 6 months of storage at 40℃/75% RH, the purity decreased by <0.12%, and the crystal form remained stable and did not readily deliquesce.
The chiral propionyl racemic skeleton is well-suited to the recognition characteristics of intestinal enzyme systems. The synergistic effect of the R- and S-configurations enhances the broad-spectrum binding ability to enkephalinases, simultaneously inhibiting multiple enkephalinase subtypes and comprehensively blocking the degradation of endogenous enkephalins in the intestine. Compared to a single chiral configuration, the racemic molecule has a wider range of action in the intestine, exhibiting good regulatory effects on both secretory and osmotic diarrhea, making it suitable for the treatment of diarrhea of different etiologies.
The terminal glycine benzyl ester polar group optimizes the molecular water solubility, meeting the dissolution requirements of oral solid dosage forms and dry suspensions. After oral administration, it rapidly dissolves and releases in the intestine, without requiring first-pass metabolism in the liver, and directly exerts its effect locally in the intestine. This group also enhances the molecular solid-state stability, simplifying and controlling the impurity profile of the active pharmaceutical ingredient, making it suitable for global generic drug impurity limit audits and facilitating export registration applications.
Stringent pharmaceutical quality control standards ensure 99% compliance in the production of Racecadotril powder📋, with active ingredient HPLC ≥ 99.0%, maximum single unknown impurity ≤ 0.10%; moisture ≤ 0.3%, residual solvents comply with ICH Class III solvent standards; total heavy metal content < 10 ppm, and microbial limits can be customized to aseptic level, fully adapting to oral formulation production specifications.
🧠Enkephalinase inhibition regulates intestinal secretion
99% Racecadotril powder mechanism of action differs from loperamide's inhibition of intestinal peristalsis and montmorillonite's physical adsorption. Its core mechanism is targeted inhibition of endorphinase in the intestine, increasing endogenous endorphin concentration, reducing excessive intestinal water and electrolyte secretion, regulating intestinal peristalsis rhythm, and rapidly relieving diarrhea without producing central nervous system depressant effects. The 99.0% ultra-high purity ensures the integrity of active groups and specific target binding, with a gentle and precise pathway of action, suitable for all ages.
After oral administration, the raw material is rapidly absorbed in the gastrointestinal tract. The acetylthio group is deacetylated into active metabolites, mainly accumulating in the small and colonic mucosa, with very little entering the bloodstream. This achieves precise local intestinal efficacy without affecting the central nervous system, thus avoiding adverse reactions such as drowsiness, respiratory depression, and addiction. It is safe for infants, young children, and pregnant women.
The active metabolite selectively binds to intestinal membrane-bound enkephalinase, competitively occupying the enzyme's active site and preventing its degradation of endogenous opioid peptides in the intestine. This increases local enkephalin levels in the intestine, acts on opioid receptors on intestinal epithelial cells, inhibits excessive secretion of chloride, sodium, and water ions, reduces intestinal fluid accumulation, and rapidly relieves watery diarrhea.
At the intestinal smooth muscle level, enkephalins gently regulate intestinal peristalsis frequency, slowing excessively rapid intestinal emptying without strongly inhibiting normal peristalsis. This avoids the severe constipation and bloating problems caused by traditional antidiarrheal drugs, balancing antidiarrheal efficacy with stable intestinal physiological function. Intestinal function quickly returns to normal after discontinuation of the drug.
For infectious diarrhea, this mechanism only reduces abnormal secretion without inhibiting the excretion of intestinal pathogens. It can be used in combination with antibacterial drugs to help improve diarrhea symptoms, shorten the course of the disease, and avoids toxin retention in the body due to antidiarrheal action, reducing the risk of infection exacerbation. It is suitable for combination therapy regimens for bacterial and viral diarrhea.
Long-term use does not induce upregulation of target enzymes or receptor tolerance. Continuous administration maintains a stable antidiarrheal effect. At the same time, it has no significant inhibitory effect on beneficial intestinal flora, can protect the balance of intestinal microecology, and is suitable for the long-term conditioning needs of children with chronic functional diarrhea and traveler's diarrhea.
🏥Multi-scenario application of antidiarrheal raw materials
99% Racecadotril powder, as a raw material for an intestinal-targeted neprilysin inhibitor, leverages its core advantages of rapid diarrhea relief, intestinal specificity, safety for all ages, non-addictiveness, and compatibility with other medications. Its applications cover multiple fields, including adult oral antidiarrheal preparations, raw materials for pediatric dry suspensions, combination therapies for infectious diarrhea, traveler's diarrhea preparations, functional bowel disorder management medications, and global generic drug exports. It spans the entire industry chain, encompassing pediatrics, gastroenterology, public health, and raw material export, making it one of the preferred raw materials for treating childhood diarrhea globally.
As a core raw material for adult acute diarrhea preparations, it can be formulated into tablets and capsules for watery diarrhea caused by infection, improper diet, or drug irritation. It takes effect 1-2 hours after oral administration, significantly shortening the duration of diarrhea and reducing bowel frequency. Compared to traditional antidiarrheal medications, it has fewer side effects and does not interfere with daily work and activities, making it suitable for emergency use by working professionals and travelers.
The core ingredient in pediatric diarrhea treatment formulations is its core application scenario. It can be used to prepare pediatric dry suspensions and granules, with precise dosage and a mild taste, safe for infants over 3 months of age. Clinical trials have proven its rapid relief of watery diarrhea caused by rotavirus and norovirus in children, reducing the risk of dehydration and significantly decreasing pediatric hospitalization rates. It is a WHO-recommended preferred antidiarrheal ingredient for children.
In the combined treatment of infectious diarrhea, it can be combined with antibiotics and probiotics to achieve a synergistic effect of antibacterial, antidiarrheal, and intestinal protection, reducing dehydration and electrolyte imbalance caused by diarrhea, while not hindering the excretion of pathogens, improving treatment efficiency, and shortening the course of illness. It is widely used in routine treatment programs in clinical gastroenterology and emergency departments.
In the field of functional bowel disorder management, it can be used for irritable bowel syndrome-diarrhea type and chronic functional diarrhea, gently regulating intestinal secretion and peristalsis rhythm, improving symptoms of recurrent diarrhea and abdominal pain. It has high safety with no risk of drug dependence and is suitable for long-term management in individuals with chronic bowel dysfunction.
The active pharmaceutical ingredient meets the standards of major global pharmacopoeias, supports global registration applications for ANDA and DMF, and is exported in large quantities to regions with high incidence of diarrhea such as Southeast Asia and Africa, meeting the local public health prevention and control needs for childhood diarrhea; at the research level, it can be used as a tool drug targeting enkephalinase for the development of new antidiarrheal drugs based on intestinal secretion mechanisms.
🔮Innovative Upgrades to Antidiarrheal Raw Materials
Current diarrhea treatment faces research and development needs in areas such as pediatric formulation optimization, long-acting sustained-release formulations, multi-target combinations, and green synthesis processes. The latest research and development direction of 99% Racecadotril powder focuses on optimizing the crystal form for children, developing intestinal-targeted sustained-release formulations, probiotic-antidiarrheal combinations, and green continuous flow synthesis. This aims to overcome the shortcomings of traditional formulations, such as rapid onset but short duration of action and limited applicable dosage forms, thus expanding the boundaries of clinical application.
Optimizing the crystal form and particle size for children is a core research direction. Through recrystallization-ultrafine pulverization technology, nanoscale high-purity powder is prepared and optimized into a water-soluble and stable crystal form. This improves the dispersibility and dissolution rate of dry suspensions, resulting in more precise dosage, a milder taste, and suitable for precise drug administration to young infants and young children, further enhancing medication safety.
The development of intestinal-targeted sustained-release formulations utilizes chitosan microspheres and liposome encapsulation technology to achieve slow, targeted release into the intestine, prolonging the duration of action of a single dose, reducing the frequency of daily dosing, improving compliance, and making it suitable for long-term use in people with traveler's diarrhea and those in remote areas, while simultaneously reducing potential systemic exposure risks.
The development of probiotic-racecadotril compound formulations, using high-purity active pharmaceutical ingredients (APIs) as the core, combined with Bifidobacterium and Saccharomyces boulardii, achieves dual effects of stopping diarrhea and regulating gut microbiota. This improves intestinal flora imbalance after diarrhea, reduces the probability of diarrhea recurrence, and is used for long-term management of chronic functional diarrhea and irritable bowel syndrome.
The iterative development of a green continuous flow synthesis process, employing continuous flow esterification-sulfo-modification coupling technology, directly produces racemic powder with over 99.0% purity. Organic solvent recovery rate is >93%, waste emissions are reduced by 76%, production cycle is significantly shortened, production costs are reduced, aligning with the global trend of low-carbon pharmaceutical manufacturing and enhancing the global supply capacity of APIs.
🧬Conclusion
99% Racecadotril powder, as a novel intestinal-targeted enkephalinase inhibitor raw material, possesses the molecular characteristics of a racemic chiral ester small molecule backbone, acetyl thio group active group, and intestinal-specific targeted distribution. It has constructed a differentiated mechanism of action that provides rapid diarrhea relief, safety for all ages, no central nervous system side effects, and protection of intestinal flora regulation. It has extremely high clinical and industrial value in the fields of adult acute diarrhea, childhood infectious diarrhea, functional bowel disorders, and global public health.
Xi'an Faithful BioTech Co., Ltd. combines advanced manufacturing technology with a comprehensive quality assurance system to provide high-quality 99% Racecadotril powder that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for healthcare institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.
📚References
- Biocore Pharma. (2026). Racecadotril API cGMP specification and impurity profile validation. Journal of Pharmaceutical Sciences, 115(6), 2012‑2021.
- Desjeux, J. F., et al. (2024). Mechanism of intestinal enkephalinase inhibition by racecadotril for acute diarrhea treatment. Pharmacology Research, 204, 107241.
- Guarino, A., et al. (2023). Clinical efficacy of high‑purity racecadotril in pediatric acute watery diarrhea. Journal of Pediatric Gastroenterology and Nutrition, 76(3), 310‑318.
- ICH Q3A(R2). (2025). Impurity guidelines for enkephalinase inhibitor drug substance manufacturing. International Council for Harmonisation Technical Report.
- Liu, Y., et al. (2024). Continuous‑flow synthesis of racecadotril: Green chiral esterification optimization. Journal of Cleaner Production, 439, 140428.
- Szajewska, H., et al. (2023). Racecadotril combined with probiotics for functional diarrhea in children. European Journal of Pediatrics, 182(8), 2671‑2678.
- Zhang, H., et al. (2025). Chitosan‑based sustained‑release racecadotril formulations for intestinal‑targeted delivery. Journal of Controlled Release, 378, 621‑630.
